PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF EPIDEMIC VIRAL RNA INFECTIOUS DISEASE

Abstract

The present invention relates to the use of pyronaridin or a pharmaceutically acceptable salt thereof, and / or artemisinin or a derivative thereof for the prevention or treatment of an epidemic viral RNA infectious disease, and more specifically, to a pharmaceutical composition for the prevention or treatment of an epidemic viral RNA infectious disease, in particular, Coronavirus Disease 2019 (COVID-19), the composition comprising a therapeutically effective amount of pyronaridin or a pharmaceutically acceptable salt thereof, and / or artemisinin or a derivative thereof, together with a pharmaceutically acceptable carrier.

Description

PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF EPIDEMIC VIRAL RNA INFECTIOUS DISEASE TECHNICAL FIELD The present invention relates to the use of pyronaridin or a pharmaceutically acceptable salt thereof, and / or artemisinin or a derivative thereof, for the prevention or treatment of epidemic RNA virus infections. More specifically, the present invention relates to a pharmaceutical composition for the prevention or treatment of epidemic RNA virus infections—specifically, coronavirus disease 2019 (COVID-19)—comprising a therapeutically effective amount of pyronaridin or a pharmaceutically acceptable salt thereof, and / or artemisinin or a derivative thereof, together with a pharmaceutically acceptable carrier. TECHNICAL BACKGROUND RNA viruses, which have RNA genomes, have a higher mutation rate than DNA viruses and readily generate mutants adapted to changes in the host and environment. Because of this property, it is difficult to control RNA viruses with antiviral agents or prophylactic vaccines. Furthermore, RNA viruses encode an RNA-dependent RNA polymerase (RdRp) that synthesizes RNA using RNA as a template in the viral genome, and the RNA polymerases of host cells—which synthesize RNA using DNA as a template—cannot act on the replication of RNA viruses. RNA viruses are divided into single-stranded positive-sense RNA viruses, single-stranded negative-sense RNA viruses, and double-stranded dsRNA viruses according to the polarity of the genome and whether or not the genomic RNA has the same polarity as mRNA. Acute viral infections—which have recently spread around the world and caused a global public health crisis—are rapidly spreading through transportation and trade from the country where the virus originates to other countries, and there is a high global demand for the development of therapeutic agents. In particular, the H1N1 influenza epidemic in 2009, the Ebola outbreaks in West Africa in 2014 and in the Democratic Republic of Congo in 2019, and the Zika virus outbreak in 2016 are all RNA virus infections. Coronaviruses are viruses that belong to the family of positive-sense, single-stranded RNA viruses, similar to the Zika virus. They have a single-stranded, positive-sense RNA genome with a size of 25–32 kb and are zoonotic viruses capable of infecting both human and animal cells, such as those of birds and mammals. Coronaviruses have a structure in which characteristic club-shaped spike proteins protrude from their outer envelopes. Coronaviruses are a family of viruses with several members, including SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV), which causes CQQI CQQI Severe Acute Respiratory Syndrome (SARS) that emerged in 2003, Middle East Respiratory Syndrome (MERS) that recently emerged in Saudi Arabia in 2012, or Coronavirus Disease 2019 (COVID-19, 2019-nCoV infection) recently declared a Public Health Emergency of International Concern (PHEIC) by the World Health Organization (WHO), respectively. SARS-CoV causes Severe Acute Respiratory Syndrome (SARS), which originated in China in 2002 and spread globally, registering a mortality rate of approximately 10% in 8,096 patients. It is usually accompanied by high fever and myalgia, and after 2–7 days a dry cough without sputum appears, causing respiratory failure in 10–20% of patients. Since an appropriate treatment has not yet been established, antibacterial agents for atypical pneumonia may be administered in combination with antiviral agents such as oseltamivir or ribavirin, or corticosteroids. MERS-CoV is assumed to be a virus transmitted from animal hosts, such as camels, to humans, causing severe acute respiratory syndrome and kidney failure. It has resulted in approximately 2,000 infections in 26 countries, including those in the Middle East, with a mortality rate of 35.6% (WHO, 2016). The incubation period is approximately 5 days and is accompanied by fever, cough, shortness of breath, and pneumonia. It was prevalent through limited transmission among family members or within healthcare facilities and commonly progressed to severe illness in individuals with underlying health conditions such as diabetes. SARS-CoV-2 (2019-nCoV) is a virus that causes COVID-19, and the first case was identified in Wuhan, China in 2019. After an incubation period of 1–14 days, various respiratory symptoms appear, ranging from mild to severe, such as cough, fever, malaise, shortness of breath, pneumonia, or acute respiratory distress syndrome. Sputum production, sore throat, and diarrhea are rare. Because there is no specific antiviral agent for SARS-CoV-2, symptomatic management is being used alone or in combination with antiviral agents previously indicated for other viral diseases. Specifically, COVID-19, the most recent outbreak among them, is spreading very rapidly with no currently available treatment or vaccine (Li et al., 2020), and an appropriate cell or animal assay system for the disease has not yet been established. Currently, medications that have been reported for clinical use or suggested in expert recommendations in China and Korea include chloroquine, remdesivir (Wang et al., 2020), lopinavir, favipiravir, ribavirin, interferon, etc., and more than 80 CQQI Clinical trials are in progress at CQQI (Maxmen et al., 2020). In particular, since SARS-CoV-2 belongs to the coronavirus family, reagents—previously known to have antiviral effects against MERS-CoV or SARS-CoV, which has approximately 79.5% nucleotide sequence homology to SARS-CoV-2—are attracting attention (Zhou et al., 2020), including reagents such as niclosamide (Xu et al., 2020). Given the cases of SARS or COVID-19, when there is close contact with a patient, the risk of infection is very high: the viruses are highly transmissible to many people in a densely populated environment through aerosolized respiratory droplets. Furthermore, acute viral infections caused by these coronaviruses are spreading rapidly through transportation and trade from the country where the virus originates to other countries, potentially causing a global public health crisis. However, the development of appropriate regimens to effectively inhibit, treat, or prevent such epidemic-causing respiratory virus pathogens has been insufficient to date. As such, there is an urgent need to develop a drug to counteract these diseases for the health and well-being of people around the world. Furthermore, although the clinical symptoms of their While CQQI respiratory infections are somewhat similar and belong to the same family of RNA viruses, there are genetic and structural differences between the viruses, and these differences are reported to affect the sensitivity and efficacy of antiviral drugs. Furthermore, these molecular-genetic differences in the viruses cause variations in transmission routes, host receptors for viral binding, transmission rates, incubation periods, and / or sites of infection, leading to differences in clinical symptoms and therapeutic efficacy. Therefore, the development and application of appropriate reagents against the target virus are crucial. Also, given the rapid transmission, high mortality, and global health and economic risks caused by respiratory infectious disease, in addition to the development of new drugs and vaccines that takes at least one to several years, it may be a very effective and cost-efficient strategy to explore the possibility of preventing, improving, or treating RNA virus infections, specifically coronavirus-induced respiratory diseases, based on the repurposing of drugs whose safety has been guaranteed by previous clinical trials and practical use experience. DESCRIPTION OF THE INVENTION TECHNICAL PROBLEM CQQI An objective of the present invention is to provide for the use of pyronaridin or a pharmaceutically acceptable salt thereof, and / or artemisinin or a derivative thereof in the prevention or treatment of epidemic RNA virus infections. Another objective of the present invention is to provide a pharmaceutical composition for the prevention or treatment of epidemic RNA virus infections comprising a therapeutically effective amount of pyronaridin or a pharmaceutically acceptable salt thereof, and / or artemisinin or a derivative thereof, together with a pharmaceutically acceptable carrier. Yet another objective of the present invention is to provide a method for the prevention or treatment of epidemic RNA virus infections by using pyronaridin or a pharmaceutically acceptable salt thereof and / or artemisinin or a derivative thereof. SOLUTION TO THE PROBLEM In order to achieve the above objective, the present invention provides a pharmaceutical composition for the prevention or treatment of epidemic RNA virus infections comprising a therapeutically effective amount of pyronaridin or a pharmaceutically acceptable salt thereof, and / or artemisinin or a derivative thereof, together with a pharmaceutically acceptable carrier. > NCNN CQQI Furthermore, the present invention provides for the use of pyronaridin or a pharmaceutically acceptable salt thereof, and / or artemisinin or a derivative thereof in the prevention or treatment of epidemic RNA virus infections. Furthermore, the present invention provides a method for the prevention or treatment of epidemic RNA virus infections comprising administering a therapeutically effective amount of pyronaridin or a pharmaceutically acceptable salt thereof, and / or artemisinin or a derivative thereof to a subject in need thereof. The present invention is described in detail below. According to one aspect of the present invention, a pharmaceutical composition for the prevention or treatment of epidemic RNA virus infections is provided, comprising a therapeutically effective amount of pyronaridin of the following Formula 1 or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier: [Formula 1] CQQI According to another aspect of the present invention, a pharmaceutical composition is provided for the prevention or treatment of epidemic RNA virus infections comprising a therapeutically effective amount of artemisinin of the following Formula 2 or a derivative thereof, together with a pharmaceutically acceptable carrier: [Formula 2] According to another aspect of the present invention, a pharmaceutical composition is provided for the prevention or treatment of epidemic RNA virus infections comprising a therapeutically effective amount of pyronaridin of Formula 1 above or a pharmaceutically acceptable salt thereof, and artemisinin of Formula 2 above or a derivative thereof, together with a pharmaceutically acceptable carrier. In one embodiment according to the present invention, examples of the pharmaceutically acceptable pyronaridin salt may include an acid addition salt that is CQQI may be in the form of phosphoric acid, sulfuric acid, hydrochloric acid, acetic acid, methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, maleic acid, or fumaric acid, but is limited to the same. In another embodiment according to the present invention, the pharmaceutically acceptable salt of pyronaridin may be pyronaridin tetraphosphate. In another embodiment according to the present invention, examples of the artemisinin derivative may include, but are not limited to, dihydroartemisinin, artesunate, artemether, and arteether. In another embodiment according to the present invention, the artemisinin derivative may be artesunate. According to another embodiment of the present invention, in the pharmaceutical composition comprising a therapeutically effective amount of pyronaridin or a pharmaceutically acceptable salt thereof, and artemisinin or a derivative thereof, together with a pharmaceutically acceptable carrier, the weight ratio of pyronaridin or a pharmaceutically acceptable salt thereof to artemisinin or a derivative thereof may be 10:1 to 1:10. In another embodiment of the present invention, the weight ratio of pyronaridin or a pharmaceutically acceptable salt thereof to artemisinin or a derivative thereof may be 1:1 to 6:1. In another embodiment of the present invention, the weight ratio of pyronaridin or a pharmaceutically acceptable salt thereof to artemisinin or a derivative thereof may be 1:1 to 6:1. The acceptable weight ratio of the same to artemisinin or a derivative thereof may be 1:1 to 4:1. In another embodiment according to the present invention, the weight ratio of pyronaridin or a pharmaceutically acceptable salt thereof to artemisinin or a derivative thereof may be 3:1. As used herein, the term pharmaceutically acceptable refers to a substance with no toxicity that is physiologically acceptable and does not limit the action of an active ingredient when administered to humans, and which usually does not cause gastrointestinal disturbances, allergic reactions such as dizziness, or similar reactions. The pharmaceutical composition of the present invention can be formulated in various ways according to the route of administration by methods known in the art, together with a pharmaceutically acceptable carrier. The route of administration is not limited to the same, but may be administered orally or parenterally. Parenteral routes of administration include, for example, various routes such as transdermal, nasal, intraperitoneal, intramuscular, subcutaneous, intravenous, and the like. When the pharmaceutical composition of the present invention is administered orally, the pharmaceutical composition of the present invention can be formulated in the form of a powder, granule, tablet, pill, coated tablet, capsule, liquid, gel, syrup, suspension, wafer, injection, suppository, and Similar CQQIs according to the method known in the art, along with a suitable oral carrier. Examples of suitable carriers may include sugars such as lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, and maltitol; starches such as corn starch, wheat starch, rice starch, and potato starch; celluloses such as cellulose, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, and reduced-substituted hydroxymethyl cellulose; and fillers such as gelatin and polyvinylpyrrolidone. In addition, if necessary, crospovidone, sodium starch glycolate, croscarmellose sodium, sodium carboxymethyl cellulose, agar, alginic acid, or sodium alginate may be added as a disintegrant.In addition, the pharmaceutical composition may also include a gluent, an anti-caking agent, a plasticizer, a lubricant, a wetting agent, a flavoring agent, an emulsifier, a preservative, and the like. Also, when administered parenterally, the pharmaceutical composition of the present invention can be formulated as an injection, suppository, transdermal application, or nasal inhalant according to known methods in the art, together with a suitable parenteral carrier. In the case of injection, it must be sterilized and protected from contamination by microorganisms such as bacteria and fungi. Examples of suitable carriers for injection include, but are not limited to, a solvent or dispersion medium containing water, ethanol, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol, and the like), a mixture thereof, and / or vegetable oil.Ideally, suitable carriers include Hanks' solution, Ringer's solution, phosphate-buffered saline (PBS), or sterile water for injection containing triethanolamine, 10% ethanol, 40% propylene glycol, and isotonic solutions such as 5% glucose. To protect the injection from microbial contamination, it may also contain various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and similar agents. In most cases, the injection may also contain an isotonic agent such as sugar or sodium chloride. These formulations are described in the commonly known prescription document in pharmaceutical chemistry (Remington's Pharmaceutical Science, 15th Edition, 1975, Mack Publishing Company, Easton, Pennsylvania). In the case of administration by inhalation, the compound for use according to the present invention can be conveniently supplied in the form of an aerosol spray from a pressurized container or nebulizer by using a suitable propellant—for example, dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide CQQI CQQI carbon or another suitable gas. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount. For example, capsules and cartridges for use in inhalers or insufflators can be formulated to contain a powder mixture relative to a suitable powder base. As with other pharmaceutically acceptable carriers, reference may be made to those described in the following document (Remington's Pharmaceutical Sciences, 19th Edition, 1995 Mack Publishing Company, Easton, Pennsylvania). In another embodiment of the present invention, pyronaridin or a pharmaceutically acceptable salt thereof was formulated together with pharmaceutically acceptable carriers. As described above, the pharmaceutically acceptable carrier that may be used in the present invention may be any one conventionally used in the pharmaceutical field. Representative examples may include lactose, dextrin, starch, pregelatinized starch, microcrystalline cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, hydroxyethyl cellulose, ethyl cellulose, methyl cellulose, polyethylene glycol, silicon dioxide, hydrotalcite, magnesium aluminum silicate, aluminum hydroxide, aluminum silicate, magnesium aluminometasilicate, bentonite, and a mixture of the CQQI themselves. In addition to the carrier, the pharmaceutical composition of the present invention may further comprise a disintegrant for rapid disintegration and dissolution upon contact with an aqueous medium when administered in vivo, a solubilizer or surfactant to enhance dissolution or absorption, and a glide or lubricant to enhance flow or lubrication. Examples of the disintegrant may include crospovidone, sodium starch glycolate, croscarmellose sodium, sodium carboxymethylcellulose, agar, alginic acid, or sodium alginate. Examples of the glide or lubricant may include colloidal silicon dioxide, silicon dioxide, talc, magnesium stearate, calcium stearate, zinc stearate, sodium stearate fumarate, stearic acid, or silicon dioxide. However, it is not limited to the examples mentioned.According to another embodiment of the present invention, a pharmaceutical composition is provided comprising 40 to 80% by weight of pyronaridin or a pharmaceutically acceptable salt thereof, 1 to 30% by weight of microcrystalline cellulose, 0.1 to 5% by weight of silicon dioxide, 1 to 10% by weight of hydroxypropyl cellulose, 1 to 10% by weight of low-substituted hydroxypropyl cellulose, 2 to 20% by weight of sodium starch glycolate, and 1 to 10% by weight of magnesium stearate. In another embodiment of the present invention, artemisinin or a derivative thereof was formulated with pharmaceutically acceptable carriers. In addition to the carrier, The pharmaceutical composition of the present invention may further comprise a disintegrant for rapid disintegration and dissolution upon contact with an aqueous medium when administered in vivo, a solubilizer or surfactant to enhance dissolution or absorption, and a gluent or lubricant to enhance flow or lubrication. Examples of carriers may include microcrystalline cellulose, lactose hydrate, mannitol, starch, pregelatinized starch, low-substituted hydroxycellulose, hydroxycellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, or hydroxypropyl methylcellulose. Examples of disintegrants may include crospovidone, sodium starch glycolate, croscarmellose sodium, sodium carboxymethylcellulose, agar, alginic acid, or sodium alginate.Examples of the slip or lubricant may include colloidal silicon dioxide, silicon dioxide, talc, magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, stearic acid, or silicon dioxide. Representative examples of the surfactant may include sodium lauryl sulfate and a derivative thereof, poloxamer and a derivative thereof, saturated polyglycolized glyceride (also called gelucire), labrasol, and various polysorbates (e.g., polyoxyethylene sorbitan monolaurate (hereinafter, Tween 20), polyoxyethylene sorbitan monopalmitate (hereinafter, Tween 40), and polyoxyethylene sorbitan monostearate). CQQI (hereafter referred to as Tween 60), polyoxyethylene monooleate sorbitan (hereinafter, Tween 8 0; i ) , sorbitan esters (e.g., sorbitan monolaurate (hereinafter, Span 20) , sorbitan monopalmitate (hereinafter, Span 40) , sorbitan monostearate (hereinafter, Span 60) , sorbitan monooleate (hereinafter, Span 80) , sorbitan trilaurate (hereinafter, Span 25) , sorbitan trioleate (hereinafter, Span 85) , sorbitan tristearate (hereinafter, Span 65) ) , cremofor, PEG-60 hydrogenated castor oil, hydrogenated castor oil PEG-40, sodium lauisil glutamate or disodium cocoamphodiacetatc. However, It is not limited to the examples mentioned. According to another embodiment of the present invention, a pharmaceutical composition is provided comprising 10 to 50% by weight of artemisinin or a derivative thereof, 30 to 70% by weight of microcrystalline cellulose, 2 to 20% by weight of low-substituted hydroxypropyl cellulose, 2 to 20% by weight of sodium starch glycolate, 0.1 to 5% by weight of silicon dioxide, 0.5 to 15% by weight of sodium lauryl sulfate, and 0.1 to 5% by weight of magnesium stearate. In another embodiment of the present invention, pyronaridin or a pharmaceutically acceptable salt thereof and artemisinin or a derivative thereof were formulated together with pharmaceutically acceptable carriers. In addition to the The pharmaceutical composition of the present invention may further comprise a disintegrant for rapid disintegration and dissolution upon contact with an aqueous medium when administered in vivo, a solubilizer or surfactant to enhance dissolution or absorption, and a gluent or lubricant to enhance flow or lubrication. Examples of carriers may include lactose, dextrin, starch, pregelatinized starch, microcrystalline cellulose, hydroxypropyl methylcellulose, low-substituted hydroxypropyl cellulose, hydroxyethyl cellulose, ethyl cellulose, methyl cellulose, polyethylene glycol, silicon dioxide, hydrotalcite, aluminum magnesium silicate, aluminum hydroxide, aluminum silicate, magnesium aluminum metasilicate, bentonite, butylhydroxytoluene, and a mixture thereof.Representative examples of surfactant may include sodium lauryl sulfate and a derivative thereof, poloxamer and a derivative thereof, saturated polyglycolized glyceride (also known as gelucire), labrasol, various polysorbate compounds (e.g., polyoxyethylene sorbitan monolaurate (hereinafter, Tween 20), polyoxyethylene sorbitan monopalmitate (hereinafter, Tween 40), polyoxyethylene sorbitan monostearate (hereinafter, Tween 60), polyoxyethylene sorbitan monooleate (hereinafter, Tween 80)), sorbitan esters (e.g., sorbitan monolaurate (hereinafter, Tween 80)). CQQI present, Span 20), sorbitan monopalmitate (hereafter Span 40), sorbitan monostearate (hereafter Span 60), sorbitan monooleate (hereafter Span 80), sorbitan trilaurate (hereafter Span 25), sorbitan trioleate (hereafter Span 85), sorbitan tristearate (hereafter Span 65), cremofor, PEG-60 hydrogenated castor oil, PEG-40 hydrogenated castor oil, sodium lauryl glutamate or disodium cocoamphodiacetate, but not They are limited to the same. Examples of the disintegrant may include crospovidone, sodium starch glycolate, croscarmellose sodium, sodium carboxymethylcellulose, agar, alginic acid, or sodium alginate. Examples of the slip or lubricant may include colloidal silicon dioxide, silicon dioxide, talc, magnesium stearate, calcium stearate, zinc stearate, sodium stearate fumarate, stearic acid, or silicon dioxide. However, it is not limited to the examples mentioned. According to another embodiment of the present invention, a pharmaceutical composition is provided comprising 15 to 60% by weight of pyronaridin or a pharmaceutically acceptable salt thereof, 5 to 20% by weight of artemisinin or a derivative thereof, 5 to 30% by weight of microcrystalline cellulose, 10 to 40% by weight of crospovidone, 2 to 15% by weight of low-substituted hydroxypropyl cellulose, 1 to 10% by weight of sodium lauryl sulfate, 5 to 30% by weight of polyethylene glycol, and 0.1 to 5% by weight. CQQI of hydroxypropyl cellulose, 0.001 to 1% by weight of butylhydroxytoluene, 0.1 to 5% by weight of silicon dioxide and 0.5 to 10% by weight of magnesium stearate. The pharmaceutical composition of the present invention can be formulated as a powder, granule, tablet, capsule, dry syrup, coating preparation, injection, suppository, transdermal administration, inhalation administration, and the like. In another embodiment of the present invention, the pharmaceutical composition of the present invention can be administered in combination with one or more additional drugs that have antiviral efficacy to prevent and treat epidemic RNA virus infections. In another embodiment of the present invention, examples of the other antiviral agents may include, but are not limited to, viral replication inhibitors, helicase inhibitors, viral protease inhibitors, and viral cell entry inhibitors. In another embodiment of the present invention, the other antiviral agent may be, for example, ribavirin, interferon, niclosamide, or a combination thereof, but is not limited to these. In another embodiment of the present invention, examples of epidemic RNA virus infectious disease may include, but are not limited to, Zika virus infection, Ebola virus infection, and respiratory diseases caused CQQI for novel influenza virus and coronavirus infections. In another embodiment of the present invention, examples of respiratory diseases caused by coronavirus infections may include, but are not limited to, Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), or Coronavirus Disease 2019 (COVID-19). In another embodiment of the present invention, the respiratory disease caused by coronavirus infection may be Coronavirus Disease 2019 (COVID-19). In the present invention, the term prevention refers to any action that inhibits or delays the occurrence, spread, and recurrence of epidemic RNA virus infections by administering the pharmaceutical composition of the present invention, and the term treatment refers to any action in which the symptoms of the disease are improved or beneficially changed by administering the pharmaceutical composition of the present invention. Furthermore, as used herein, the term therapeutically effective amount refers to an amount that exhibits a higher response than a negative control, and preferably refers to an amount sufficient to prevent or treat epidemic RNA virus infections. The therapeutic dose for a patient is generally 50 to 2,000 mg / day, and more preferably 100 to 1,000 mg / day, depending on the severity of the condition or whether it is administered alone or in combination with other drugs. This may be administered once daily or in divided doses orally or parenterally. However, the therapeutically effective amount may be appropriately changed depending on several factors, such as the type and severity of the disease, the patient's age, body weight, health status, and gender, the route of administration, and the duration of treatment. Although the present invention describes the prevention and treatment of epidemic RNA virus infections in humans, preferably respiratory diseases caused by coronavirus infections in humans, and more preferably COVID-19 in humans, the present invention may be useful for the treatment of infectious RNA viruses, specifically viruses in Coronaviridae that cause respiratory diseases, and more specifically the virus that causes COVID-19, in animals and humans. The problems of the present invention are not limited to the technical problems mentioned above, and other unmentioned technical problems would be clearly understood by a person skilled in the art from the following description. Furthermore, the foregoing description does not limit the claimed invention in any way; moreover, the combination of features discussed is not absolutely necessary for CQQI the inventive solution. ADVANTAGEOUS EFFECTS OF THE INVENTION The present invention provides a pharmaceutical composition for the prevention or treatment of epidemic RNA virus infections comprising a therapeutically effective amount of pyronaridin or a pharmaceutically acceptable salt thereof, and / or artemisinin or a derivative thereof as the active ingredient(s). The pharmaceutical composition according to the present invention can be effectively used for the prevention or treatment of epidemic RNA virus infections—for example, respiratory diseases such as COVID-19 caused by coronavirus. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a concentration-response curve that considers the inhibitory effects against SARS-CoV-2 and cytotoxicity by pretreatment with pyronaridin tetraphosphate—which is one of the active ingredients of the present invention—when measured at 24 hours post-infection. Figure 2 is a concentration-response curve that considers the inhibitory effects against SARS-CoV-2 and cytotoxicity by co-treatment with pyronaridin tetraphosphate when measured at 24 hours post-infection. CQQI Figure 3 shows the results in which the The inhibitory effects against SARS-CoV-2 by the co-treatment of artesunate—one of the active ingredients of the present invention—were measured at 24 hours and 48 hours post-infection and compared with those by chloroquine as a control. Figure 4 shows the results comparing the inhibitory effects of combining pyronaridin tetraphosphate and artesunate in various ratios in SARS-CoV-2 infected cells. The inhibitory effects against the virus were compared at 24 hours and 48 hours post-infection using the optimal ratio. Figure 5 shows concentration-response curves that consider the inhibitory effects against SARS-CoV-2 and cytotoxicity measured 24 hours and 48 hours post-infection in the human lung cell line, Calu-3 cells, compared to those by hydroxychloroquine as a control, when pyronaridin tetraphosphate or artesunate was treated simultaneously with virus infection. Figure 6 is a concentration-response curve that considers the inhibitory effects against SARS-CoV-2 by post-infection treatment with pyronaridin tetraphosphate or artesunate in the human lung cell line, Calu-3 cells, when measured 48 hours after drug treatment. Figure 7 shows the results in which the CQQI hamsters were infected with SARS-CoV-2 and orally administered low or high doses of pyronaridin tetraphosphate and artesunate in combination in a 3:1 ratio 1 hour post-infection once a day for 3 days, or high dose of pyronaridin tetraphosphate alone 25 hours post-infection, and when viral titers in the lungs were analyzed on day 4 post-infection and compared to the virus-inoculated control group in which no drugs were administered. METHOD FOR THE INVENTION Later in this document, the constitutions and effects of the present invention will be described in more detail by way of examples. However, these examples are merely illustrative, and the scope of the present invention is not limited to them. Example 1: Preparation of the pyronaridin tetraphosphate monotablet Hydroxypropyl cellulose was dissolved in ethanol to prepare a binding solution. After wet granulation of pyronaridin tetraphosphate using the prepared binding solution, the resulting product was dried and granulated. Low-substituted hydroxypropyl cellulose, sodium starch glycolate, microcrystalline cellulose, and silicon dioxide were mixed. After lubrication by adding magnesium stearate, tablets were prepared. CQQI through tablet formation. [Table 1] Ingredient content (mg / preparation) Pyronaridine tetraphosphate360 Microcrystalline cellulose48 Silicon dioxide6 Hydroxypropiocellulose12 Low-substituted hydroxypropyl cellulose 18 Sodium starch glycolate24 Magnesium stearate12 Example 2: Preparation of the artesunate monotablet Silicon dioxide and sodium lauryl sulfate were sieved using a sieve. The sieved silicon dioxide and sodium lauryl sulfate were mixed with artesunate, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and sodium starch glycolate, lubricated by adding magnesium stearate, and then formed into tablets. The resulting product was coated with a film coating agent. [Table 2] Ingredient content (mg / preparation) Artesunato100 Microcrystalline cellulose228 Low-substituted hydroxypropyl cellulose30 CQQI Sodium starch glycolate20 Silicon dioxide5 Sodium lauryl sulfate12 Magnesium stearate5 Film coating agent (Opadry) 12 Example 3: Preparation of the pyronaridin tetraphosphate / artesunate combination tablet Polyethylene glycol as a melt dispersant carrier, butylhydroxytoluene and artesunate as an active ingredient were mixed, melted by heating, then rapidly cooled and finely pulverized. Microcrystalline cellulose, low-substituted hydroxypropyl cellulose, crospovidone, and magnesium stearate were then mixed with this mixture to obtain Mixture 1. After dissolving hydroxypropyl cellulose in ethanol, pyronaridin tetraphosphate was wet-granulated, dried, and granulated to obtain Mixture 2. Mixture 1, Mixture 2, sodium lauryl sulfate, silicon dioxide, and crospovidone were mixed, and then magnesium stearate was added to lubricate the mixture, followed by tablet formation. The resulting product was coated with a film coating agent. [Table 3] Ingredient content (mg / preparation) > your NCNNC CQQI Artesunate 60 Pyronaridine tetraphosphate 180 Microcrystalline cellulose 93 Crospovidone 120 Low-substituted hydroxypropyl cellulose 38 Sodium lauryl sulfate 23 Polyethylene glycol 90 Hydroxypropyl cellulose 6 Butylhydroxytoluene 0.12 Silicon dioxide 4.5 Magnesium stearate 16.5 Film coating agent (Opadry) 20 In order to determine whether pyronaridin or a salt thereof, and artemisinin or a derivative thereof of the present invention have antiviral activity against coronavirus, the reagents were treated alone and in combination 5 as in the following Experimental Examples, and the inhibitory rates against viral infection were evaluated. Experimental Example 1: Evaluation of the antiviral effects of pyronaridin tetraphosphate (pretreatment) In Experimental Example 1, before infecting 10 cells with SARS-CoV-2 (a Korean isolate), pyronaridin tetraphosphate was pretreated for 1 hour, and the inhibitory efficacy against virus infection was evaluated. CQQI 1) Preparation of viruses and host cells Vero cells were purchased from the American Type Culture Collection (ATCC) and incubated at 37°C with 5% CO2 in Dulbecco's Modified Eagle Medium (DMEM), supplemented with 10% heat-inactivated fetal bovine serum (FBS) and an antibiotic. SARS-CoV-2 was provided by the Korea Centers for Disease Control and Prevention (KCDC). After viral amplification, viral titers were determined by a plaque assay by counting the viral plaques formed on the cells used for viral amplification during infection. 2) Determination of antiviral efficacy using immunofluorescence staining imagesVero cells were seeded at a density of 1.2 × 10⁴ cells per well in qClear plates. Twenty-four hours prior to the experiment, the cells were pretreated for 1 hour with a series of 10 drug dilutions in the culture medium at a concentration range of 0.05–50 μM. SARS-CoV-2 was then inoculated into the cells at a multiplicity of infection (MOI) of 0.0125. Twenty-four hours post-infection, the cells were fixed with 4% formaldehyde, and the infected cells were analyzed by immunofluorescence staining using an antibody against the SARS-CoV-2 N protein. The infection rate was calculated as the ratio of the number of infected cells to the total number of cells compared to positive and negative controls using image analysis software. The antiviral effect of the drug is represented as a concentration-response curve, and using the Graph Prism analysis program (Ver.8), 50% effective concentration (EC50, concentration that inhibits virus infection-induced cytotoxicity by 50%) and 50% cytotoxic concentration (CC50, the concentration of the compound that causes damage in 50% of cells compared to normal cells) was calculated as shown in Equation 1. <Ecuación 1> Sigmoidal model, Y= Bottom + (Top - Bottom) / (1 + (IC50 / X) Slope) As shown in Figure 1, in the case of SARS-CoV-2-infected Vero cells, a 70% virus inhibition rate was observed at a 50 μM concentration of pyronaridin, but cytotoxicity was also increased by 17% by drug pretreatment. Vero cells were isolated from the kidney epithelial cells of African green monkeys (Chlorocebus sp.) and are known as type I IFN-γ-deficient cells. In the previous study, when the in vitro antiviral efficacy of pyronaridin against Ebola virus was measured in Vero cells, no antiviral activity was observed at concentrations below CC50 (CC50 = 1.3 μM), but when inoculated into human-derived HeLa cells, a higher CC50 was reported, and antiviral activity was observed. CQQI CQQI showed a non-toxic concentration (EC50 = 0.42–1.12 μM, CCso = 3.1 μM). Furthermore, pyronaridin significantly inhibited mortality and viral infection rate in mouse models stimulated with the Ebola virus (Lañe et al., 2015). It is well known that the efficacy of antiviral agents can differ in in vitro or in vivo assay systems depending on differences in the characteristics of the host cells tested and their intracellular immune signaling pathways (Lañe et al., 2015), and thus, human-derived host cell-based assays were further established, and the antiviral efficacy of pyronaridin was also confirmed in several cell lines and animal studies. Experimental Example 2: Inhibitory effects of pyronaridin tetraphosphate against the SARS-CoV-2 virus (co-treatment) In Experimental Example 2, the inhibitory effects of pyronaridin against viral infection were evaluated when cells were co-treated at the time of infection with SARS-CoV-2 (a Korean isolate). Chloroquine is known to exhibit antiviral efficacy by increasing endosomal pH, leading to inhibition of viral binding to cells and glycosylation of host receptors to SARS-CoV (Vincent et al., 2005). Since pyronaridin—which has a similar structure to chloroquine—was also expected to act via a similar mechanism, pyronaridin was treated concurrently at the time of viral infection, and its antiviral efficacy was measured. By optimizing some of the experimental conditions used in Experimental Example 1, the experiment was conducted under test conditions with relatively low cytotoxicity. 1) Preparation of viruses and host cells Vero cells were incubated at 37°C with 5% COc in Dulbecco's Modified Eagle Medium (DMEM), supplemented with 10% heat-inactivated fetal bovine serum (FBS) and an antibiotic. SARS-CoV-2 was provided by the Korea Centers for Disease Control and Prevention (KCDC). After viral amplification, viral titers were determined by qRT-PCR, which measures RNA copy numbers. 2) Measuring antiviral efficacy using RNA copy numbers After dissolving pyronaridin tetraphosphate in DMSO, it was diluted to a concentration of 0.033–100 μM using culture medium. Twenty-four hours before the experiment, SARS-CoV-2 was inoculated into Vero cells seeded in a 96-well plate at a density of 2 × 10⁴ cells / well (MOI = 0.01), and culture medium containing various drug dilutions was added to each well. Twenty-four hours post-infection, the cell supernatant was collected, RNA was extracted, and qRT-PCR was performed against the RdRp gene. The antiviral efficacy of the drug was CQQI CQQI was analyzed by comparing the number of viral RNA copies with the drug to that with the control. A drug-response concentration curve was plotted with the rate of inhibition of viral infection (% inhibition) of the virus titer calculated inversely from the number of RNA copies, and the 50% effective concentration (ECs, the concentration that inhibits the virus titer by 50%) was calculated using the Graph Prism analysis program (Ver. 8), as in Experimental Example 1. 3) Measurement of cytotoxicity (% of cytotoxicity) Cytotoxicity was measured using a tetrazolium salt-based assay (WST-1). WST-1 is converted to a chromogenic substance called formazan by mitochondrial dehydrogenases, which are present only in living cells. After adding 10 pL of the WST-1 premix to each well, the cells were incubated for an additional 1 hour, and the amount of formazan produced was estimated from its absorbance measured by ELISA. The cytotoxic concentration 50% (CC50, the concentration of the compound that causes damage in 50% of cells compared to normal cells) was calculated. As a result, as shown in Figure 2, pyronaridin exhibited the antiviral effect in a concentration-dependent manner when co-treated, and cytotoxicity was observed at some of the higher concentrations, but antiviral activity against the virus COOI SARS-CoV-2, more than 90% inhibition, at non-cytotoxic concentrations (ECso = 8.27 μM, CCso = 11.54 μM; selectivity index, SI>1.40). Experimental Example 3: Inhibitory effects of artesunate against SARS-CoV-2 (co-treatment) In Experimental Example 3, the antiviral efficacy of artesunate was measured under the same experimental conditions as in Experimental Example 2. 1) Preparation of the virus and host cell The Vero cells and viruses were prepared in the same way as shown in Experimental Example 2. 2) Measuring antiviral efficacy using RNA copy numbers Artesunate was dissolved in DMSO and then diluted to concentrations of 3.13, 12.5 and 50 μM using the medium. Twenty-four hours before the experiment, SARS-CoV-2 was inoculated into Vero cells seeded in a 96-well plate at a density of 2 × 10⁴ cells / well (MOI = 0.01), and culture medium containing various drug dilutions was added to each well. At 24 and 48 hours post-infection, the cell supernatant was collected, and qRT-PCR was performed against the RdRp gene to calculate the viral titer and the rate of viral infection inhibition (% inhibition), as shown in Experimental Example 2. Chloroquine was used as the control. > your NCNNC 35 3) Measurement of cytotoxicity (% cytotoxicity) Cytotoxicity was measured in the same way as shown in Experimental Example 2. As shown in Figure 3, artesunate exhibited concentration-dependent antiviral activity, showing an 83% inhibition rate against the virus at a concentration of 50 μM. At 12.5 μM, inhibition rates were 40% and 51% at 24 hours post-infection (24 hpi) and 48 hours post-infection (48 hpi), respectively. Furthermore, at 3.13 μM, the inhibition rate was 39% at 48 hours post-infection. There was no significant cytotoxicity under any of the tested conditions. Artesunate had a lower EC50 and a slower onset time for SARS-CoV-2 inhibition compared to pyronaridin or chloroquine used as controls, but it had a longer duration of antiviral effect, exhibiting a pattern in which the rate of viral inhibition increased slowly over time. Experimental example 4: Inhibitory effects of the pyronaridin tetraphosphate / artesunate combination against SARS-CoV-2 Unlike chloroquine, which showed no antiviral effect in guinea pig models infected with the Ebola virus, pyronaridin significantly improved viral titer and survival rate in mouse models stimulated with the Ebola virus. As such, it was assumed that CQQI Chloroquine may have different mechanisms of action, including immunomodulatory mechanisms such as the type 1 IFN-1 pathway (Lañe et al., 2019). Artesunate also showed antiviral efficacy against Ebola virus in in vitro assays, but weaker than pyronaridin (Gignox et al., 2016). Therefore, in Experimental Example 4, changes in antiviral efficacy were evaluated according to the combination treatment with different ratios of the two drugs. 1) Preparation of viruses and host cells The Vero cells and the virus were prepared in the same way as shown in Experimental Example 2. 2) Measuring antiviral efficacy using RNA copy numbers Pyronaridine tetraphosphate and artesunate were dissolved in DMSO and diluted to various concentrations using media in several combination ratios, such as 1:1, 3:1, 10:1, etc. Twenty-four hours before the experiments, SARS-CoV-2 was inoculated into Vero cells seeded in a 96-well plate at a density of 2 x 10⁴ cells / well (MOI = 0.01), and culture media containing various drug dilutions were added to each well. Twenty-four hours post-infection, the cell supernatant was collected, and qRT-PCR was performed against the gene CQQI RdRp to calculate virus titer and virus infection inhibition rate (% inhibition) as shown in Experimental Example 2. When 10 μM of pyronaridin tetraphosphate and 3.3 μM of artesunate were treated in combination, virus titers were measured at 24 and 48 hours post-infection each, and compared with chloroquine and lopinavir used as controls. 3) Measurement of cytotoxicity (% of cytotoxicity) Cytotoxicity was measured in the same way as shown in Experimental Example 2. As shown in Figure 4, the antiviral effect of artesunate in combination with pyronaridin was higher than that of artesunate alone, and the antiviral effect increased with increasing proportions of pyronaridin in the combination. Specifically, when 10 μM of pyronaridin tetraphosphate and 3.3 μM of artesunate were combined (3:1 ratio), the combination exhibited a 90–100% inhibition rate against viral infection, a higher antiviral effect than that of chloroquine or lopinavir used as controls. In this case, the inhibition rate against infection was maintained for up to 48 hours. No significant cytotoxicity was observed in any of the combination ratios shown in Figure 4, and when 10 μM of pyronaridin tetraphosphate and 3.3 μM of artesunate were treated in combination, cytotoxicity was observed. CQQI lower compared to treatment with 10 μM of pyronaridin tetraphosphate alone (49.5% decrease). Experimental Example 5: Inhibitory effects of pyronaridin tetraphosphate or artesunate against SARS-CoV-2 in human lung cell lines (co-treatment) Species differences have been reported between antiviral activity in humans and other animals, such as in receptor structures. Therefore, to confirm efficacy in human lung cell lines, in Experimental Example 5, when SARS-CoV-2 (a Korean isolate) was inoculated into Calu-3 cells (a human lung cell line), pyronaridin phosphate or artesunate was used and evaluated for efficacy in inhibiting viral infection. The inhibitory effects of pyronaridin tetraphosphate or artesunate against viral infection were evaluated in human lung cell lines, Calu-3 cells, when the cells were treated at the time of SARS-CoV-2 infection (a Korean isolate). 1) Preparation of viruses and host cells Calu-3 cells were incubated at 37 °C with 5% CO2 in Dulbecco's Modified Eagle Medium (DMEM), supplemented with 10% heat-inactivated fetal bovine serum (FBS) and an antibiotic. SARS-CoV-2 was provided by the Korea Centers for Disease Control and Prevention (KCDC). 2) Measurement of antiviral efficacy using CQQI RNA copy numbers After dissolving in DMSO, pyronaridin tetraphosphate was diluted to a concentration of 0.033–100 μM using the medium. Twenty-four hours before the experiment, SARS-CoV-2 was inoculated into Vero cells seeded in a 96-well plate at a density of 2*10⁴ cells / well (MOI=0.01), and culture media containing various dilutions of the drug were added to each well. At 24 hours and 48 hours post-infection, qRT-PCR was performed against the RdRp gene as shown in Experimental Example 2. A drug-response concentration curve was plotted with the rate of inhibition of viral infection (% inhibition) of the virus titer inversely calculated from the number of RNA copies, and the 50% effective concentration (EC50, the concentration that inhibits the virus titer by 50%) was calculated using the Graph Prism analysis program (Ver. 8), as shown in Experimental Example 1. 3) Measurement of cytotoxicity (% of cytotoxicity) Cytotoxicity was measured in the same way as in Experimental Example 2. As a result, as shown in Figure 5, both pyronaridin and artesunate exhibited concentration-dependent antiviral effects in human lung cell lines when co-treated at the time of infection. Furthermore, both 24 hours post-40 CQQI infection (24 hpi) as well as 48 hours post-infection (48 hpi), exhibited antiviral activities against SARS-CoV-2, with over 90% inhibition, at non-cytotoxic concentrations (pyronaridin 48 hours post-infection IC50 = 8.58 μM, CC50 > 100 μM, SI selectivity index > 11.66; artesunate 48 hours post-infection IC50 = 0.45 μM, CC50 > 100 μM, SI selectivity index > 220.8). Specifically, in the case of artesunate, the effect was significantly increased in human lung cell lines compared to that in monkey kidney cell lines, Vero cells. In contrast, hydroxychloroquine showed no antiviral effect at less than 50 μM in human lung cell lines, while hydroxychloroquine showed antiviral efficacy in monkey cell lines. Experimental Example 6: Inhibitory effects of post-infection treatment with pyronaridin tetraphosphate or artesunate against SARS-CoV-2 in human lung cell lines In Experimental Example 6, either pyronaridin tetraphosphate or artesunate was each treated in Calu-3 cells at 0, 2, 4, 6, 8, 10, 12, 24, and 36 hours after inoculation with SARS-CoV-2 (a Korean isolate), and the number of hours the inhibitory effect of each drug was retained against virus infections was assessed. 1) Preparation of viruses and host cells The Calu-3 cells and viruses were prepared from the CQQI in the same way as shown in Experimental Example 5. 2) Determination of antiviral efficacy using the viral plaque assay After dissolving pyronaridin tetraphosphate and artesunate in DMSO, each solution was diluted to 12.5 μM using the medium. One hour after inoculation with SARS-CoV-2 (MOI=0.1), the supernatant was removed, and the Calu-3 cells were washed, followed by the addition of DMEM culture medium containing 2% bovine serum. Drug-containing culture media were added at 0, 2, 4, 6, 8, 10, 12, 24, and 36 hours each. Forty-eight hours after each drug treatment, cell supernatants were collected, and a plaque assay was performed—in which plaques generated by infection with the infectious virus were counted on Vero cells, the cells used for virus amplification. The layer of DMEM-F12 medium containing 2% agarose was placed on the layer of infected Vero cells, and the number of plates was counted using crystal violet counterstaining, after incubation for 72 hours.The antiviral efficacy of the drug was analyzed using the rate of inhibition of viral infection (% inhibition) of the virus titer inversely calculated from the number of plaques formed and compared with the control. As a result, as shown in Figure 6, maximum antiviral efficacy was shown when 12.5 μM of CQQI pyronaridin was treated (>99% inhibition when added up to 6 hours post-infection, >94% inhibition when added up to 12 hours post-infection, and 90% inhibition when added up to 24 hours post-infection). On the other hand, treatment with 12.5 μM artesunate showed 92-96% inhibition when added up to 6 hours post-infection, >90% inhibition when added up to 12 hours post-infection, and 48% inhibition when added up to 24 hours post-infection. Experimental Example 7: Inhibitory effects of the pyronaridin tetraphosphate / artesunate combination against SARS-CoV-2 in animal models of COVID-19 In Experimental Example 7, pyronaridin tetraphosphate and artesunate (combination in a 3:1 ratio) were administered orally to hamsters infected with SARS-CoV-2 (a Korean isolate) to evaluate antiviral efficacy in vivo in animals. 1) Preparation of viruses and hamsters for inoculation with SARS-CoV-2 The SARS-CoV-2 virus was provided by the Korea Centers for Disease Control and Prevention (KCDC). Syrian hamsters—which showed high susceptibility to SARS-CoV-2 and had low supply constraints—were used as experimental animal models, and SARS-CoV-2 (1 × CQQI 106PFU / 100 μΣ) was inoculated into each of both nasal passages of the hamster with an amount of 50 μΣ. 2) Measurement of in vivo antiviral efficacy using the plaque assay One hour after nasal inoculation with SARS-CoV-2, pyronaridin tetraphosphate (180 mg / kg or 360 mg / kg) and artesunate (60 mg / kg or 120 mg / kg) were administered orally as a 3:1 combination once daily for 3 days, and the in vivo antiviral efficacy of the two-drug combination against SARS-CoV-2 was evaluated. As the comparator, pyronaridin 360 mg / kg alone was administered orally once 25 hours post-infection to assess the duration of post-infection efficacy of pyronaridin alone. Both the pyronaridin tetraphosphate and artesunate solutions were precisely prepared before use, thoroughly dissolved in 5% sodium bicarbonate, and administered orally. As control groups, a normal (Simulated) control group in which the virus was not inoculated and a vehicle control group in which only a solvent was inoculated at the same time were used.At 4 days post-infection, both the left and right lobes of the lungs were removed, the virus was extracted, and the virus titers in the lung tissues were analyzed by a plaque assay as described in Experimental Example 6. The viral titer in the lungs quantified by a plaque assay was normalized to the total weight (g) of the lung tissues, and then converted to the log value to calculate the final titer (Logic plaque-forming unit / g, LogicPFU / g). As a result, as shown in Figure 7, at 4 days post-infection, the reduction in the infectious virus titer in lung tissues was statistically significant in both of the co-administration groups of pyronaridin tetraphosphate (P)-artesunate (A) 180 / 60 mg / kg and 360 / 120 mg / kg [median LogioPFU: 8.30 for the virus-stimulated vehicle control group vs. 7.22 for the PA 180 / 60 mg / kg co-administration group (p<0.001); vs. 7.61 for the PI 360 / 120 mg / kg co-administration group (p=0.046)]. Furthermore, when pyronaridin tetraphosphate was administered orally only, a significant decrease in the infectious virus titer was observed in lung tissue when the high dose of 360 mg / kg was administered, and a significant inhibitory effect was observed even if administered once within 25 hours post-infection [LogioPFU median 8.30 for the virus-stimulated vehicle control group versus the single high-dose 25 hpi administration group 7.22 (p<0.001) ] .

Claims

1. A pharmaceutical composition for the prevention or treatment of epidemic RNA virus infections, characterized in that it comprises a therapeutically effective amount of pyronaridin or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

2. A pharmaceutical composition for the prevention or treatment of epidemic RNA virus infections, characterized in that it comprises a therapeutically effective amount of artemisinin or a derivative thereof, together with a pharmaceutically acceptable carrier.

3. A pharmaceutical composition for the prevention or treatment of epidemic RNA virus infections, characterized in that it comprises a therapeutically effective amount of pyronaridin or a pharmaceutically acceptable salt thereof, and artemisinin or a derivative thereof, together with a pharmaceutically acceptable carrier.

4. The pharmaceutical composition according to claim 1 or 3, characterized in that the pharmaceutically acceptable salt of pyronaridin is selected from the group consisting of phosphate, sulfate, hydrochloride, acetate, methanesulfonate, benzenesulfonate, toluenesulfonate, maleate, and fumarate.

5. The pharmaceutical composition according to claim 4, characterized in that the pharmaceutically acceptable salt of pyronaridin is pyronaridin tetraphosphate.

6. The pharmaceutical composition according to claim 3, characterized in that a weight ratio of pyronaridin or a pharmaceutically acceptable salt thereof to artemisinin or a derivative thereof is 10:1 to 1:

10.

7. The pharmaceutical composition according to claim 6, characterized in that the weight ratio of pyronaridin or a pharmaceutically acceptable salt thereof to artemisinin or a derivative thereof is 1:1 to 6:

1.

8. The pharmaceutical composition according to claim 7, characterized in that the weight ratio of pyronaridin or a pharmaceutically acceptable salt thereof to artemisinin or a derivative thereof is 3:

1.

9. The pharmaceutical composition according to claim 2 or 3, characterized in that the artemisinin derivative is selected from the group consisting of dihydroartemisinin, artesunate, artemether and arteether.

10. The pharmaceutical composition according to claim 9, characterized in that the artemisinin derivative is artesunate.

11. The pharmaceutical composition according to any one of claims 1 to 3, characterized in that it further comprises at least one other antiviral agent. CQQI 12. The pharmaceutical composition according to CQQI claim 11, characterized in that the other antiviral agent is selected from the group consisting of a viral replication inhibitor, a helicase inhibitor, a viral protease inhibitor, and a viral cell entry inhibitor.

13. The pharmaceutical composition according to claim 12, characterized in that the other antiviral agent is selected from the group consisting of ribavirin, interferon, niclosamide and a combination thereof.

14. The pharmaceutical composition according to any one of claims 1 to 3, characterized in that the epidemic RNA virus infection is selected from the group consisting of Zika virus infection, Ebola virus infection, respiratory diseases caused by novel influenza virus, or coronavirus infections.

15. The pharmaceutical composition according to claim 14, characterized in that the respiratory disease caused by coronavirus infection is selected from the group consisting of Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and Coronavirus Disease 2019 (COVID-19).

16. The pharmaceutical composition according to claim 15, characterized in that the respiratory disease caused by coronavirus infection is Coronavirus Disease 2019 (COVID-19).

17. Use of a therapeutically effective amount of > s NCNNC 48 pyronaridin or a pharmaceutically acceptable salt thereof, characterized in that it is for the manufacture of a medicament for the prevention or treatment of epidemic RNA virus infections.

18. Use of a therapeutically effective amount of artemisinin or a derivative thereof, characterized in that it is for the manufacture of a drug for the prevention or treatment of epidemic RNA virus infections.

19. Use of a therapeutically effective amount of pyronaridin or a pharmaceutically acceptable salt thereof and artemisinin or a derivative thereof, characterized in that it is for the manufacture of a medicament for the prevention or treatment of epidemic RNA virus infections.

20. The use according to claim 17 or 19, characterized in that the pharmaceutically acceptable salt of pyronaridin is selected from the group consisting of phosphate, sulfate, hydrochloride, acetate, methanesulfonate, benzenesulfonate, toluenesulfonate, maleate, and fumarate.

21. The use according to claim 20, characterized in that the pharmaceutically acceptable salt of pyronaridin is pyronaridin tetraphosphate.

22. The use according to claim 19, characterized in that the weight ratio of pyronaridin or a pharmaceutically acceptable salt thereof to artemisinin or a derivative thereof is 10:1 to 1:

10.

23. The use according to claim 22, characterized in that the weight ratio of pyronaridin or a pharmaceutically acceptable salt thereof to artemisinin or a derivative thereof is 1:1 to 6:

1.

24. The use according to claim 23, characterized in that the weight ratio of pyronaridin or a pharmaceutically acceptable salt thereof to artemisinin or a derivative thereof is 3:

1.

25. The use according to claim 18 or 19, characterized in that the artemisinin derivative is selected from the group consisting of dihydroartemisinin, artesunate, artemether, and arteether.

26. The use according to claim 25, characterized in that the artemisinin derivative is artesunate.

27. Use in accordance with any of claims 17 to 19, characterized in that the medicinal product further comprises at least one other antiviral agent.

28. The use according to claim 27, characterized in that the other antiviral agent is selected from the group consisting of a viral replication inhibitor, a helicase inhibitor, a viral protease inhibitor, and a viral cell entry inhibitor.

29. The use according to claim 28, characterized in that the other antiviral agent is selected from the group consisting of ribavirin, interferon, niclosamide and a CQOI combination thereof.

30. Use in accordance with any of claims 17 to 19, characterized in that the epidemic RNA virus infectious disease is selected from group 5 consisting of Zika virus infection, Ebola virus infection, respiratory diseases caused by novel influenza virus, or coronavirus infections.

31. The use according to claim 30, characterized in that the respiratory disease caused by the coronavirus infection is selected from the group consisting of Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and Coronavirus Disease 2019 (COVID-19).

32. The use according to claim 31, 15 characterized in that the respiratory disease caused by coronavirus infection is Coronavirus Disease 2019 (COVID-19).